Your browser doesn't support javascript.
loading
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Riches, Lucy C; Trinidad, Antonio G; Hughes, Gareth; Jones, Gemma N; Hughes, Adina M; Thomason, Andrew G; Gavine, Paul; Cui, Andy; Ling, Stephanie; Stott, Jonathan; Clark, Roger; Peel, Samantha; Gill, Pendeep; Goodwin, Louise M; Smith, Aaron; Pike, Kurt G; Barlaam, Bernard; Pass, Martin; O'Connor, Mark J; Smith, Graeme; Cadogan, Elaine B.
Afiliação
  • Riches LC; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Trinidad AG; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Hughes G; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Jones GN; Translational Medicine, Oncology R&D, Oncology, AstraZeneca, Cambridge, United Kingdom.
  • Hughes AM; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Thomason AG; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Gavine P; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Cui A; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Ling S; Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Stott J; Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Clark R; Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Peel S; Quantitative Biology, Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Gill P; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Goodwin LM; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Smith A; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Pike KG; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Barlaam B; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Pass M; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • O'Connor MJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Smith G; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Cadogan EB; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. elaine.cadogan@astrazeneca.com.
Mol Cancer Ther ; 19(1): 13-25, 2020 01.
Article em En | MEDLINE | ID: mdl-31534013
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Piridinas / Quinolinas / Radiossensibilizantes / Neoplasias de Mama Triplo Negativas / Proteínas Mutadas de Ataxia Telangiectasia Limite: Animals / Humans / Male Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Piridinas / Quinolinas / Radiossensibilizantes / Neoplasias de Mama Triplo Negativas / Proteínas Mutadas de Ataxia Telangiectasia Limite: Animals / Humans / Male Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido